The Japanese Journal of Dermatology
Online ISSN : 1346-8146
Print ISSN : 0021-499X
ISSN-L : 0021-499X
Volume 131 , Issue 10
Showing 1-6 articles out of 6 articles from the selected issue
Guidance
Seminar for Medical Education
Original Articles
  • Manami Okuzawa, Yukari Zenke, Ryota Shibuya, Kyoko Tsumura, Toshiaki N ...
    2021 Volume 131 Issue 10 Pages 2287-2296
    Published: September 20, 2021
    Released: September 21, 2021
    JOURNAL RESTRICTED ACCESS

    Cutaneous manifestations of systemic lupus erythematosus (SLE) are occasionally resistant to conventional treatment options.

    Belimumab is the first biological agent for the treatment of SLE, it was approved in 2017. We report three cases of SLE with refractory cutaneous manifestations successfully treated with belimumab.

    Case 1: A 27-year-old man developed multiple lupus erythematosus profundus lesions on his scalp, face, and trunk.

    Case 2: A 33-year-old woman had chilblain lupus erythematosus on her nose.

    Case 3: A 17-year-old female adolescent developed refractory butterfly-shaped erythema and multiple incomplete hair loss patches scattered on her scalp associated with erythema. All the patients received oral corticosteroids and immunosuppressants for SLE; however, none of them had an sufficient response. Belimumab was effective not only against systemic symptoms but also successful in treating the severe cutaneous manifestations of SLE; therefore, we could reduce the oral corticosteroid dosage. Based on these findings, we propose belimumab as an effective treatment option for refractory cutaneous manifestations of SLE.

    Download PDF (2504K)
Erratum
feedback
Top